BT
BTCY.US Biotricity Inc
- Market cap
- USD 1.21M
- P/E
- -
- P/B
- 29.92x
- ROE
- -
- Dividend yield
- 1.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BTCY.US undervalued?
Graham numberThe Graham number of Biotricity Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biotricity Inc fundamental analysis
No fundamental analysis for Biotricity Inc yet.
Biotricity Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biotricity Inc
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It also offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a H…
Full company profileBiotricity Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biotricity Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 398K | 1.42M | 3.38M | 7.65M | 9.64M | 12.1M | 13.8M | 16.0M | 17.1M |
| Gross Profit | 0.00 | 0.00 | 59.9K | 486K | 1.27M | 4.57M | 5.44M | 8.36M | 10.6M | 12.9M | 14.1M |
| Operating Income | -5.94M | -7.72M | -8.59M | -10.9M | -13.4M | -16.7M | -15.4M | -8.83M | -2.45M | 1.69M | 632K |
| EBITDA | -5.94M | -7.72M | -11.7K | -247K | -707K | -18.6M | -16.1M | -6.73M | -3.21M | 2.44M | 1.93M |
| Net Income | -7.81M | -8.62M | -8.59M | -11.1M | -15.5M | -29.1M | -18.7M | -14.1M | -8.42M | -2.40M | -3.84M |
| EPS | -1.81 | -1.72 | -1.54 | -1.85 | -2.48 | -3.85 | -2.15 | -1.57 | -0.39 | -0.09 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 474K | 929K | 491K | 2.00M | 4.44M | 16.7M | 6.51M | 5.94M | 5.64M | 6.45M | 6.02M |
| Total Liabilities | 4.86M | 756K | 2.27M | 5.00M | 11.3M | 18.8M | 26.4M | 35.9M | 35.7M | 39.4M | 39.7M |
| Shareholders' Equity | -4.38M | 173K | -1.78M | -3.00M | -6.83M | -2.14M | -19.8M | -30.0M | -30.0M | -33.0M | -33.7M |
| Cash & Short-term Investments | 425K | 844K | 63.6K | 950K | 2.20M | 12.1M | 570K | 786K | 365K | 150K | 467K |
| Total Debt | 1.56M | - | 868K | 2.34M | 4.71M | 15.4M | 19.5M | 23.9M | 26.1M | 27.1M | 26.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.75M | -4.87M | -5.22M | -7.86M | -11.1M | -15.2M | -13.5M | -6.69M | -2.38M | -719K | 2.03M |
| Capital Expenditure | 0.00 | 0.00 | 29.8K | 29.8K | 29.8K | 29.8K | 5.00 | 0.00 | 3.00 | 0.00 | 20.00 |
| Free Cash Flow | -3.75M | -4.87M | -5.22M | -7.86M | -11.1M | -15.2M | -13.5M | -6.69M | -2.38M | -719K | 2.03M |
| Ratios | |||||||||||
| ROE | - | -4,977.7% | - | - | - | - | - | - | - | - | - |
| ROA | -1,649.2% | -927.9% | -1,751.1% | -552.1% | -349.1% | -174.7% | -286.6% | -237.2% | -149.3% | -37.3% | -63.7% |
| Net Profit Margin | - | - | -2,157.7% | -780.6% | -457.7% | -380.8% | -193.6% | -116.8% | -61.1% | -15.0% | -22.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Biotricity Inc dividends
- Dividend yield
- 1.98%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 24.0K | 0.00 | - |
| 2025 | USD 30.0K | 0.00 | - |
| 2024 | USD 18.0K | 0.00 | - |
| 2023 | USD 947K | 0.11 | - |
| 2022 | USD 966K | 0.13 | - |
| 2021 | USD 603K | 0.10 | - |
| 2020 | USD 180K | 0.03 | - |
| 2019 | USD 180K | 0.03 | - |
| 2018 | USD 180K | 0.04 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jul 3, 2023.
Who owns Biotricity Inc
- Insiders 1.18%
- Institutions 1.22%
- Public & others 97.60%
- Shares outstanding 20.1M
- Free float 17.0M
Top funds holding BTCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Total Market Index Strategy | 1.20K | 0.00% | +42.20% | Jun 2024 |
Top institutions holding BTCY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Strengthening Families & Communities, LLC | 48.3K | 0.24% | 0.00% | Jun 2026 |
| Sfam, LLC | 18.3K | 0.09% | 0.00% | Mar 2026 |
Biotricity Inc company profile
- Company name
- Biotricity Inc
- Ticker
- BTCY.US
- Exchange
- USA Stocks
- Listed since
- Feb 18, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 46
- Fiscal year end
- March
- Address
- 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065
- Phone
- 800 590 4155
- Website
- biotricity.com
About Biotricity Inc
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It also offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which support medical practitioners to gather data, and regularly monitor and treat patients with two or more chronic care conditions; Bioheart that offers preventative care and disease management solutions; and Biokit, a remote patient monitoring kit for cardiac patients that had other chronic conditions such as hypertension or COPD. Biotricity, Inc. is based in Redwood City, California.
Biotricity Inc management
7- Dr. Waqaas Al-Siddiq Ph.D.Founder, President, CEO & Chairman · born 1985
- Mr. S. John AyanoglouChief Financial Officer · born 1966
- Mr. Amjad TalpurSenior Director of Operations
- Mr. Matt ZabelVice President of Sales & Strategy
- Mr. Amir AliChief Development Officer
- Mr. Spencer LaDowCISO and Executive VP of Engineering & Regulatory
- Dr. Fareeha SiddiquiExecutive Vice President of Healthcare Solutions